MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

Decernotinib

CAS No. : 944842-54-0

MCE 站：Decernotinib

产品活性：Decernotinib 是一种有效的，可口服的 JAK3 抑制剂，对 JAK3，JAK1，JAK2 和 TYK2 的 K_i 值分别为 2.5，11，13 和 11 nM。

研究领域：Epigenetics  |  Stem Cell/Wnt  |  JAK/STAT Signaling

作用靶点：JAK

In Vitro: Decernotinib (VX-509) is a potent JAK3 inhibitor, with K_is of 2.5, 11, 13 ａnd 11 nM for JAK3, JAK1, JAK2, ａnd TYK2, respectively. Decernotinib potently blocks T-cell proliferation with a mean IC₅₀ of 170 ± 101 nM, ａnd inhibits IL-2-stimulated T-cell proliferation (IC₅₀, 140 ａnd 400 nM). VX-509 is also cytotoxic to B-cell in response to CD40L ａnd IL-4 (IC₅₀, 50 nM).

In Vivo: Decernotinib (VX-509, 10, 25, or 50 mg/kg, p.o.) significantly ａnd dose-dependently inhibits the increases in ankle diameter ａnd paw weight occuring in response to collagen injections in rats. Decernotinib potently alleviates cartilage damage ａnd bone resorption in rats. Decernotinib (10, 25, or 50 mg/kg, p.o., b.i.d.) suppresses ear edema in a mouse model of delayed-type hypersensitivity.

相关产品：Drug Repurposing Compound Library Plus  |  Clinical Compound Library Plus  |  Bioactive Compound Library Plus  |  Epigenetics Compound Library  |  Immunology/Inflammation Compound Library  |  JAK/STAT Compound Library  |  Kinase Inhibitor Library  |  Stem Cell Signaling Compound Library  |  Clinical Compound Library  |  Anti-Aging Compound Library  |  Drug Repurposing Compound Library  |  Differentiation Inducing Compound Library  |  Reprogramming Compound Library  |  Anti-Breast Cancer Compound Library  |  Anti-Pancreatic Cancer Compound Library  |  Anti-Blood Cancer Compound Library  |  Ruxolitinib  |  AG490  |  Tofacitinib  |  Baricitinib  |  Deucravacitinib  |  Upadacitinib  |  Fedratinib  |  Peficitinib  |  Pacritinib  |  Filgotinib  |  Zotiraciclib  |  WP1066  |  Itacitinib  |  Momelotinib  |  Delgocitinib  |  Ritlecitinib  |  Abrocitinib  |  AZD-1480  |  AT9283  |  Brepocitinib P-Tosylate  |  CHZ868  |  Gandotinib  |  Cerdulatinib  |  JANEX-1  |  Lestaurtinib  |  Cucurbitacin I  |  Ropsacitinib

品牌介绍:
•   MCE (MedChemExpress) 拥有数百种全球独家化合物，我们致力于为全球科研客户提供*新*全的高品质小分子活性化合物；
•   10,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；
•   设有专业的实验中心和严格的质控、验证体系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
•   产品的生物活性多经各国客户实验验证；
•   Nature, Cell, Science 等多种期刊及制药收录了MCE客户的科研成果；
•   专业团队跟踪*新的制药及生命科学研究进展，为您提供全球*新的活性化合物；
•   与世界各大制药公司及知名科研机构建立了长期的合作。